Clinical Trial Update: Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sunitinib malate in patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-01-15